What is the Medilepsy app studying for epilepsy?

The Medilepsy app is being studied to see if its AI-personalized version can improve medication adherence and readiness for transitioning care among underserved young people with epilepsy. The University of Central Florida is leading this research to better support self-management in this group. Participants use either the AI-enhanced or standard app version to compare outcomes.

Who may be eligible for this epilepsy clinical trial?

People aged 14 to 24 with a diagnosis of epilepsy who are prescribed anti-seizure medication may be eligible. Participants must live in Florida, belong to an underserved population, and be able to use a mobile device. Both males and females can join. Please review eligibility criteria for more details.

Is there any cost to participate in this epilepsy clinical trial?

Study-related care, including the study app and all trial visits, is provided at no cost. Personal expenses such as travel may vary and are not guaranteed to be covered. Participants should plan accordingly for any additional costs.

Actively Recruiting

Phase Not Applicable

Age: 14Years - 24Years

All Genders

ID07445074

Mobile App Study Using AI to Improve Medication and Transition Readiness for Adolescents and Young Adults with Epilepsy in Florida

Led by University of Central Florida · Updated on 2026-05-29

200

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

Researchers are evaluating the effectiveness of an AI-personalized mobile app called Medilepsy in improving medication adherence and transition readiness among underserved adolescents and young adults with epilepsy, ages 14 to 24, in Florida. This study compares the AI-enhanced version of the app with a standard version that does not include AI personalization. The research focuses on key outcomes including medical adherence, usability, and language experience. Participants are randomly assigned to one of two groups the intervention group uses the AI-personalized Medilepsy app with an interactive Smart Chatbot that provides tailored prompts, adaptive education, and personalized support for epilepsy self-management. The comparison group receives a standard version of the Medilepsy app, which offers static prompts and general educational content without personalized feedback. The study lasts 3 to 6 months, during which participants use their assigned app version. During the study, participants will be monitored for medication adherence and transition readiness skills through app usage and assessments. Researchers will evaluate the usability of the app at the end of the 3 to 6 month period. The study collects data on how well the AI features support epilepsy management compared to the standard app version. Safety and participant engagement are also observed throughout the trial duration.

CONDITIONS

Brief Title

AI-Based Mobile Intervention on Medication Non-Adherence and Transition

Who Can Participate

Age: 14Years - 24Years

All Genders

Eligibility Criteria

You may qualify if you...

Diagnosed with epilepsy
Currently prescribed anti-seizure medicine (ASMs)
Identified as part of an underserved population, such as being from a racial or ethnic group underrepresented in healthcare or having low income
Aged 14-17 years and able to provide assent, with a parent or legal guardian present to receive app notifications
Aged 18-24 years and able to provide informed consent
Able to read, speak, and write in English
Resides in Florida
Receives outpatient medical services

You will not qualify if you...

Does not own a mobile device with internet access
Has a history of severe intellectual disability
Unable to operate a mobile device using keyboard or touchscreen
Resides in an in-patient setting
Adults unable to provide consent
Pregnant women
Prisoners

Research Team

Michelle Tall, PhD, RN, FAES

Amoy Fraser, PhD, CCRP, PMP

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here